Cover Image
市場調查報告書

黑皮質素4受體:開發中產品分析

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 359406
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
黑皮質素4受體:開發中產品分析 Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018
出版日期: 2018年03月13日 內容資訊: 英文 66 Pages
簡介

本報告提供黑皮質素4受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

黑皮質素4受體概要

治療藥的開發

黑皮質素4受體:開發中的產品 - 各開發階段

黑皮質素4受體:開發中的產品 - 各治療範圍

黑皮質素4受體開發中的產品 - 各適應症

黑皮質素4受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

黑皮質素4受體:企業開發中的產品

黑皮質素4受體:大學/機關開發中的產品

黑皮質素4受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

黑皮質素4受體的治療藥開發企業

  • AstraZeneca Plc
  • Mallinckrodt Plc
  • Obexia AG
  • Palatin Technologies, Inc.
  • Pfizer Inc.
  • Retrophin Inc.
  • Rhythm Pharmaceuticals, Inc.

黑皮質素4受體:藥物簡介

黑皮質素4受體:暫停中的計劃

黑皮質素4受體:開發中止的產品

黑皮質素4受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1359TDB

Summary:

According to the recently published report 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018'; Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

The report 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018' outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Metabolic Disorders, Musculoskeletal Disorders, Women's Health, Central Nervous System, Genetic Disorders, Infectious Disease and Male Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Diabetes, Erectile Dysfunction, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Gouty Arthritis (Gout), Lipodystrophy, Metabolic Syndrome and Prader-Willi Syndrome (PWS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
  • The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Melanocortin Receptor 4 (MC4R) - Overview
    • Melanocortin Receptor 4 (MC4R) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • MallInckrodt Plc
    • Palatin Technologies Inc
  • Melanocortin Receptor 4 (MC4R) - Drug Profiles
    • (liraglutide + setmelanotide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AQB-565 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bremelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • corticotropin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PL-8905 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setmelanotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • setmelanotide ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize MC4-R for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Melanocortin Receptor 4 (MC4R) - Dormant Products
  • Melanocortin Receptor 4 (MC4R) - Discontinued Products
  • Melanocortin Receptor 4 (MC4R) - Product Development Milestones
    • Featured News & Press Releases
      • Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
      • Jan 04, 2018: Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
      • Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting
      • Oct 31, 2017: Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
      • Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)
      • Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
      • Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
      • Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
      • Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
      • Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
      • Jun 27, 2017: Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
      • Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert
      • Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update
      • Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis
      • Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Indication, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018
  • Number of Products under Investigation by Universities/Institutes, H1 2018
  • Products under Investigation by Universities/Institutes, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Pipeline by AstraZeneca Plc, H1 2018
  • Pipeline by MallInckrodt Plc, H1 2018
  • Pipeline by Palatin Technologies Inc, H1 2018
  • Dormant Products, H1 2018
  • Dormant Products, H1 2018 (Contd..1), H1 2018
  • Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development by Stage of Development, H1 2018
  • Number of Products under Development by Therapy Areas, H1 2018
  • Number of Products under Development by Top 10 Indications, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top